ZA201902335B - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- ZA201902335B ZA201902335B ZA2019/02335A ZA201902335A ZA201902335B ZA 201902335 B ZA201902335 B ZA 201902335B ZA 2019/02335 A ZA2019/02335 A ZA 2019/02335A ZA 201902335 A ZA201902335 A ZA 201902335A ZA 201902335 B ZA201902335 B ZA 201902335B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical compounds
- activity
- compound
- cbp
- benzimidazole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1617627.3A GB201617627D0 (en) | 2016-10-18 | 2016-10-18 | Pharmaceutical compounds |
| PCT/GB2017/053153 WO2018073587A1 (en) | 2016-10-18 | 2017-10-18 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201902335B true ZA201902335B (en) | 2024-11-27 |
Family
ID=57680679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/02335A ZA201902335B (en) | 2016-10-18 | 2019-04-12 | Pharmaceutical compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10647704B2 (enExample) |
| EP (1) | EP3529240B1 (enExample) |
| JP (1) | JP7082616B2 (enExample) |
| CN (1) | CN110036002B (enExample) |
| AU (1) | AU2017346454B2 (enExample) |
| DK (1) | DK3529240T3 (enExample) |
| ES (1) | ES2824814T3 (enExample) |
| GB (1) | GB201617627D0 (enExample) |
| HU (1) | HUE052107T2 (enExample) |
| WO (1) | WO2018073587A1 (enExample) |
| ZA (1) | ZA201902335B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2019055877A1 (en) | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| IL279734B2 (en) | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| TW202102494A (zh) | 2019-03-15 | 2021-01-16 | 美商弗瑪治療公司 | 抑制環amp-反應元件-結合蛋白(creb) |
| CN112574189B (zh) * | 2019-09-27 | 2024-05-31 | 海创药业股份有限公司 | 一种ep300/cbp抑制剂 |
| CN112574191B (zh) * | 2019-09-29 | 2024-01-23 | 南京圣和药业股份有限公司 | 异噁唑杂环类化合物及其应用 |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| TW202227429A (zh) * | 2020-11-06 | 2022-07-16 | 大陸商貝達藥業股份有限公司 | Ｐ３００抑制劑、包含其的藥物組合物、其應用及製備其的方法 |
| CN116670129A (zh) * | 2020-12-31 | 2023-08-29 | 南京明德新药研发有限公司 | 苯并咪唑类化合物及其应用 |
| CN114989158A (zh) * | 2021-03-02 | 2022-09-02 | 复旦大学 | 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用 |
| CN117645603A (zh) * | 2022-09-05 | 2024-03-05 | 复旦大学 | p300溴结构域抑制剂及其药用组合物及其应用 |
| KR20250113346A (ko) | 2024-01-17 | 2025-07-25 | 주식회사 엘지화학 | CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물 |
| TW202542135A (zh) | 2024-01-17 | 2025-11-01 | 南韓商Ｌｇ化學股份有限公司 | 作為ＣＢＰ／ｐ３００抑制劑之新穎化合物和含有彼作為活性成分以預防或治療癌症、發炎病症或自體免疫疾病之醫藥組成物 |
| CN122535608A (zh) | 2024-01-17 | 2026-08-07 | 株式会社Lg化学 | 用作cbp/p300抑制剂的新型化合物以及包含其作为活性成分的用于预防或治疗癌症、炎性障碍或自身免疫性疾病的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20070129353A1 (en) * | 2005-11-08 | 2007-06-07 | Michael Kahn | Alpha-helix mimetics and method relating to the treatment of cancer stem cells |
| US8501957B2 (en) | 2008-12-10 | 2013-08-06 | China Medical University | Benzimidazole compounds and their use as anticancer agents |
| US9005670B2 (en) * | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| EP2397471A1 (en) | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| CN105473581B (zh) * | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| EP3632915A1 (en) * | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| CA2966452A1 (en) | 2014-12-17 | 2016-06-23 | Samuel David Brown | Substituted bicyclic compounds as bromodomain inhibitors |
| GB201506658D0 (en) * | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| CN114605387A (zh) | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| GB201617630D0 (en) * | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
-
2016
- 2016-10-18 GB GBGB1617627.3A patent/GB201617627D0/en not_active Ceased
-
2017
- 2017-10-18 EP EP17790814.2A patent/EP3529240B1/en active Active
- 2017-10-18 WO PCT/GB2017/053153 patent/WO2018073587A1/en not_active Ceased
- 2017-10-18 DK DK17790814.2T patent/DK3529240T3/da active
- 2017-10-18 CN CN201780072397.7A patent/CN110036002B/zh active Active
- 2017-10-18 HU HUE17790814A patent/HUE052107T2/hu unknown
- 2017-10-18 US US16/341,650 patent/US10647704B2/en active Active
- 2017-10-18 ES ES17790814T patent/ES2824814T3/es active Active
- 2017-10-18 AU AU2017346454A patent/AU2017346454B2/en active Active
- 2017-10-18 JP JP2019520591A patent/JP7082616B2/ja active Active
-
2019
- 2019-04-12 ZA ZA2019/02335A patent/ZA201902335B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201617627D0 (en) | 2016-11-30 |
| EP3529240B1 (en) | 2020-08-05 |
| US10647704B2 (en) | 2020-05-12 |
| EP3529240A1 (en) | 2019-08-28 |
| US20190263788A1 (en) | 2019-08-29 |
| HUE052107T2 (hu) | 2021-04-28 |
| AU2017346454B2 (en) | 2022-02-17 |
| AU2017346454A1 (en) | 2019-05-02 |
| CA3039643A1 (en) | 2018-04-26 |
| WO2018073587A1 (en) | 2018-04-26 |
| ES2824814T3 (es) | 2021-05-13 |
| DK3529240T3 (da) | 2020-09-07 |
| NZ752356A (en) | 2025-02-28 |
| CN110036002A (zh) | 2019-07-19 |
| CN110036002B (zh) | 2022-08-30 |
| JP7082616B2 (ja) | 2022-06-08 |
| JP2019535658A (ja) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX384438B (es) | Compuestos farmacéuticos. | |
| PH12019501396A1 (en) | Compositions and methods for inhibiting arginase activity | |
| PH12019501685A1 (en) | Quinazone compound | |
| PH12017502407A1 (en) | Fused pyrimidine compound or salt thereof | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| PH12019501639B1 (en) | Jak1 selective inhibitors | |
| TN2017000374A1 (en) | TGF-β INHIBITORS | |
| WO2016044641A3 (en) | Carm1 inhibitors and uses thereof | |
| NZ629456A (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| GEP20156289B (en) | New aminopyrazoloquinazolines | |
| GEP20166484B (en) | Protein kinase inhibitors | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| NZ732511A (en) | Small molecule inhibitors of egfr and pi3k | |
| MX2020005659A (es) | Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. | |
| MX2017007607A (es) | Inhibidores de necrosis celular y metodos relacionados. | |
| PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| TN2016000560A1 (en) | Heteroaryl compounds for kinase inhibition | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| TW201613577A (en) | Pharmaceutical combinations | |
| PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |